Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Cancer Surgery Trials

Washington D.C., District of Columbia

Cancer surgery and procedure trials in Washington D.C., DC

43 cancer surgery and procedure studies are recruiting participants at sites in Washington D.C. as of November 18, 2026, according to ClinicalTrials.gov. Cancer Surgery Trials can help you understand your options and connect with a study team.

Call (888) 350-9284
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Washington D.C. at a glance

  • 43 studies are recruiting at a site in Washington D.C..
  • By phase: Phase 1/2 (5), Phase 2 (10), Phase 2/3 (1), Phase 3 (19), No phase (4), Observational (4). Studies of devices and behavioral approaches have no phase.
  • By sponsor: university, hospital or other (26), government (16), industry (1).
  • By research area: Lymphoma (12), Lung Cancer (11), Prostate Cancer (7), Breast Cancer (5), Melanoma (4), Pancreatic Cancer (4).
  • Most recent update to one of these records: November 18, 2026.

Breast cancer studies recruiting in Washington D.C.

Basic details from each study's public record (the 30 most recently updated of 43). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Sibley Memorial Hospital
    Registry record
    NCT06058377 · updated
  2. Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

    • Observational
    • Ages 40 to 75
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study sites
    MedStar Georgetown University Hospital · MedStar Washington Hospital Center
    Registry record
    NCT05334069 · updated
  3. ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study sites
    MedStar Georgetown University Hospital · MedStar Washington Hospital Center
    Registry record
    NCT06876714 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Washington D.C., DC on ClinicalTrials.gov.

Lung cancer studies recruiting in Washington D.C.

  1. Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    MedStar Georgetown University Hospital
    Registry record
    NCT06287775 · updated
  2. Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Kaiser Permanente-Capitol Hill Medical Center · MedStar Georgetown University Hospital · MedStar Washington Hospital Center
    Registry record
    NCT04267848 · updated
  3. Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

    • Phase 3
    • Ages 70 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    George Washington University Medical Center
    Registry record
    NCT06096844 · updated
  4. Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    George Washington University Medical Center
    Registry record
    NCT04181060 · updated
  5. Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    MedStar Georgetown University Hospital
    Registry record
    NCT03191149 · updated
  6. Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

    • Phase 2
    • From 18 minutes
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study site
    Kaiser Permanente-Capitol Hill Medical Center
    Registry record
    NCT06031688 · updated
  7. Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study site
    Kaiser Permanente-Capitol Hill Medical Center
    Registry record
    NCT06616584 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Washington D.C., DC on ClinicalTrials.gov.

Prostate cancer studies recruiting in Washington D.C.

  1. Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    MedStar Georgetown University Hospital
    Registry record
    NCT03866382 · updated
  2. Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    ECOG-ACRIN Cancer Research Group
    Study site
    Sibley Memorial Hospital
    Registry record
    NCT04423211 · updated
  3. Evaluating Safety and Efficacy of Prostate-sparing Radical Cystectomy

    • No phase
    • Ages 18 and older
    • Male participants
    Sponsor
    Johns Hopkins University
    Study site
    Sibley Memorial Hospital
    Registry record
    NCT05792722 · updated
  4. Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study sites
    MedStar Georgetown University Hospital · MedStar Washington Hospital Center
    Registry record
    NCT06931340 · updated
  5. Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    NRG Oncology
    Study site
    George Washington University Medical Center
    Registry record
    NCT05946213 · updated
  6. Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    SWOG Cancer Research Network
    Study site
    George Washington University Medical Center
    Registry record
    NCT03678025 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Washington D.C., DC on ClinicalTrials.gov.

Melanoma studies recruiting in Washington D.C.

  1. Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Sibley Memorial Hospital
    Registry record
    NCT05896839 · updated
  2. Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Regeneron Pharmaceuticals
    Study site
    George Washington University Medical Faculty Associates
    Registry record
    NCT06585410 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Washington D.C., DC on ClinicalTrials.gov.

Lymphoma studies recruiting in Washington D.C.

  1. Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    MedStar Georgetown University Hospital
    Registry record
    NCT03739814 · updated
  2. Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

    • Phase 2
    • Up to 365 days
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Children's National Medical Center
    Registry record
    NCT06317662 · updated
  3. Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Sibley Memorial Hospital
    Registry record
    NCT06337318 · updated
  4. The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

    • Phase 1/2
    • Up to age 22
    • All sexes
    Sponsor
    PedAL BCU, LLC
    Study site
    Children's National Medical Center
    Registry record
    NCT04726241 · updated
  5. Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Eastern Cooperative Oncology Group
    Study site
    Sibley Memorial Hospital
    Registry record
    NCT06724237 · updated
  6. Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Sibley Memorial Hospital
    Registry record
    NCT04269902 · updated
  7. A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • Ages 1 to 30
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Children's National Medical Center · MedStar Georgetown University Hospital
    Registry record
    NCT04546399 · updated
  8. A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    • Phase 3
    • Ages 5 to 60
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Children's National Medical Center · MedStar Georgetown University Hospital
    Registry record
    NCT05675410 · updated
  9. A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • From 366 days, up to 46 years
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Children's National Medical Center · MedStar Georgetown University Hospital
    Registry record
    NCT06124157 · updated
  10. CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

    • Phase 1/2
    • From 12 months, up to 21 years
    • All sexes
    Sponsor
    Children's Oncology Group
    Study site
    Children's National Medical Center
    Registry record
    NCT04870944 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Washington D.C., DC on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in Washington D.C.

  1. APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Sibley Memorial Hospital
    Registry record
    NCT04858334 · updated
  2. Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers

    • Observational
    • Ages 50 to 75
    • All sexes
    Sponsor
    ECOG-ACRIN Cancer Research Group
    Study site
    MedStar Georgetown University Hospital
    Registry record
    NCT04239573 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Washington D.C., DC on ClinicalTrials.gov.

Ask about studies near Washington D.C.

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a surgery or another procedure, as each study is coded in the registry.

Cancer Surgery Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 350-9284

or send a short form

How should we reach you?

Call